C-reactive protein and incident diabetes in patients with arterial disease

European Journal of Clinical Investigation

Volumn 43, Issue 10, 2013, Pages 1052-1059

  Verhagen, Sandra N ^a   Wassink, Annemarie M J ^a   Van der Graaf, Yolanda ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

HsCRP; Inflammation; Insulin resistance; Manifest vascular disease; Obesity; Type 2 diabetes.

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTERY DISEASE; ARTICLE; BODY MASS; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HOMEOSTASIS MODEL OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SUBCUTANEOUS FAT; THICKNESS;

HSCRP; INFLAMMATION; INSULIN RESISTANCE; MANIFEST VASCULAR DISEASE; OBESITY; TYPE 2 DIABETES;

AORTIC ANEURYSM, ABDOMINAL; ARTERIES; C-REACTIVE PROTEIN; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES;

EID: 84884702574     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12142     Document Type: Article

References (38)

1. Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 1990;70:1114tdthom#x2013;8.
2. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29:2959tdthom#x2013;71.
3. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005;46:1112tdthom#x2013;3.
4. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004;145:2273tdthom#x2013;82.
5. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015tdthom#x2013;25.
6. Stern MP. Diabetes and cardiovascular disease. The tdthom#x201C;common soiltdthom#x201D; hypothesis. Diabetes 1995;44:369tdthom#x2013;74.
7. Marinkovic S, Jahreis GP, Wong GG, Baumann H. IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol 1989;142:808tdthom#x2013;12.
8. Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132tdthom#x2013;40.
9. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384tdthom#x2013;9.
10. Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010;33:804tdthom#x2013;10.
11. Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007;56:872tdthom#x2013;8.
12. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799tdthom#x2013;805.
13. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-7.
14. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596tdthom#x2013;600.
15. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009;52:1040tdthom#x2013;7.
16. Liu S, Tinker L, Song Y, Rifai N, Bonds DE, Cook NR et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 2007;167:1676tdthom#x2013;85.
17. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327tdthom#x2013;34.
18. Tabak AG, Kivimaki M, Brunner EJ, Lowe GD, Jokela M, Akbaraly TN et al. Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. Eur J Endocrinol 2010;163:89tdthom#x2013;95.
19. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, KoenigW et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007;30:854tdthom#x2013;60.
20. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29tdthom#x2013;38.
21. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924tdthom#x2013;9.
22. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15:773tdthom#x2013;81.
23. Wassink AM, van der Graaf Y, van Haeften TW, Spiering W, Soedamah-Muthu SS, Visseren FL. Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases. A cohort study. Diabet Med 2011;28:932tdthom#x2013;40.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412tdthom#x2013;9.
25. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735tdthom#x2013;52.
26. Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005;28:2497tdthom#x2013;500.
27. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016tdthom#x2013;21.
28. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004;53:693tdthom#x2013;700.
29. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93tdthom#x2013;9.
30. Thorand B, Baumert J, Doring A, Herder C, Kolb H, Rathmann W et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006;184:216tdthom#x2013;24.
31. Faber DR, van der Graaf Y, Westerink J, Visseren FL. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis 2010;212:274tdthom#x2013;80.
32. Becker A, Bos G, de Vegt F, Kostense PJ, Dekker JM, Nijpels G et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J 2003;24:1406tdthom#x2013;13.
33. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001;161:1717tdthom#x2013;23.
34. D'Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 2007; 50:840-9.
35. Xu JW, Morita I, Ikeda K, Miki T, Yamori Y. C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol 2007;21:564-73.
36. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959tdthom#x2013;65.
37. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 2010;5:e14328.
38. Wassink AM, van der Graaf Y, Soedamah-Muthu SS, Spiering W, Visseren FL. Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. Diab Vasc Dis Res 2008;5:114tdthom#x2013;22.